Bristol-Myers’ Loss to Gilead Over Immunotherapy Will Stand

The U.S. Court of Appeals for the Federal Circuit rejected a request by Bristol-Myers that it reconsider an August decision to toss a $1.2 billion verdict against Gilead and its Kite unit over a pioneering technique known as CAR-T, in which the T cells of a person’s own immune system are modified to attack cancer cells.

• A three-judge panel ruled in August that a patent owned by Bristol-Myers’ Juno Therapeutics and the Sloan Kettering Institute for Cancer Research is invalid
  • Gilead’s Kite unit successfully argued that the patent “cover an enormous number (millions of billions)” of potential candidates so didn’t ...